In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

(2017) Xinyu Qin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections

(2017) Gregory G. Stone et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections

(2017) Massimo Sartelli et al.   World Journal of Emergency Surgery

In Vitro Activity of Ceftazidime-Avibactam Against Isolates in a Phase 3 Open-label Clinical Trial for Complicated Intra-abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-negative Pathogens

(2016) Gregory G. Stone et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

(2016) Boudewijn L. M. de Jonge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012–2014

(2016) Helio S. Sader et al.   Surgical Infections

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

(2015) Joseph Solomkin et al.   CLINICAL INFECTIOUS DISEASES

The β-Lactams Strike Back: Ceftazidime-Avibactam

(2015) Evan J. Zasowski et al.   PHARMACOTHERAPY

Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48

(2014) Sushmita D. Lahiri et al.   ACS Chemical Biology

Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections

(2014) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

(2014) Henry Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study

(2014) Massimo Sartelli et al.   World Journal of Emergency Surgery

Proliferation and significance of clinically relevant β-lactamases

(2013) Karen Bush   Annals of the New York Academy of Sciences

Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005–2010

(2013) Tim Babinchak et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value

(2013) Robert K. Flamm et al.   JOURNAL OF CHEMOTHERAPY

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

(2009) T. Stachyra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY